Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MENHIR: Methylprednisolone and N-acetylcysteine in hepatic resections
2012-003213-34Phase 2Active
- Sponsor
- Humanitas Research Hospital
- Start
- Nov 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatic neoplasm, liver cancer, liver ischemia-reperfusion injury and 1 more comparing Methylprednisolone + N-acetylcysteine with Placebo (2 arms). Primary endpoint: Modulation of ischemia-reperfusion injury. Started Nov 2012; status: active.
02
Drugs
methylprednisoloneacetylcysteine
03
Conditions
hepatic neoplasmliver cancerliver ischemia-reperfusion injuryhepatic failure
Beyond the preview
Go deeper on 2012-003213-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003213-34.